Search Results

You are looking at 191 - 200 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco

. 2 – 5 Improvement in CT regimens in recent years is yet another compelling reason to invest in trials evaluating preoperative therapy in PaC. For example, multiagent CT regimens, such as FOLFIRINOX 24 and gemcitabine/nab-paclitaxel, 25 , 26 which

Full access

Trends in Neoadjuvant Approaches in Pancreatic Cancer

Lingling Du and Andrea Wang-Gillam

therapy has been a main challenge in the neoadjuvant setting. In the meantime, recent studies have shown that both FOLFIRINOX and nab-paclitaxel plus gemcitabine improved survival in patients with advanced PDAC. 21 , 22 These regimens were noted to have

Full access

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

followed by paclitaxel. Figure 5 Reframed thinking on adjuvant therapy: the generation lineages and chains of interference. Therefore, the overall data suggest a benefit with anthracycline either in lieu of or added to CMF. However, not all anthracycline

Full access

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino

paclitaxel with either cisplatin or carboplatin, 114 – 116 docetaxel with cisplatin, 117 , 118 or single-agent fluoropyrimidine (fluorouracil or capecitabine), 85 , 119 , 120 docetaxel, 77 , 121 or paclitaxel. 122 , 123 Docetaxel, carboplatin, and

Full access

Bladder Cancer

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho

which 80 patients were treated using twice-daily irradiation plus cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine, the 5-year overall survival was 56%. 71 In these trials, the complete response rate ranged from 59% to 81

Full access

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Joseph Chao, Prajnan Das, Crystal S. Denlinger, Paul Fanta, Farhood Farjah, Charles S. Fuchs, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, Catherine Linn, A. Craig Lockhart, Quan P. Ly, Mary F. Mulcahy, Mark B. Orringer, Kyle A. Perry, George A. Poultsides, Walter J. Scott, Vivian E. Strong, Mary Kay Washington, Benny Weksler, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar

patients with advanced gastric cancer. Irinotecan (single agent or in combination with other cytotoxic agents) has also been evaluated in the second line setting. 71 – 76 In a randomized phase III study that compared irinotecan with paclitaxel in 223

Full access

Combined Modality Therapy of Esophageal Cancer

Rosalyn A. Juergens and Arlene Forastiere

Edited by Kerrin G. Robinson

Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus [abstract] . J Clin Oncol 2007 ; 25 ( Suppl

Full access

Is the Battle Over Bevacizumab Coverage Looming?

Catherine Larkin

bevacizumab should no longer be marketed for breast cancer. The FDA began the process of finalizing that recommendation on December 16, 2010, the same day the European Medicines Agency said bevacizumab should still be used with paclitaxel in treating breast

Full access

Controversies in the Locoregional Management of Head and Neck Cancer

David M. Brizel, William Lydiatt, and A. Dimitrios Colevas

Concurrent Systemic Therapy The most common anticancer agents used concurrently with radiation in the curative treatment of squamous cell carcinoma of the head and neck (SCCHN) include cisplatin, carboplatin, paclitaxel, docetaxel, cetuximab, and 5

Full access

NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer

Thomas W. Flaig

phase III trial, which randomly assigned 542 patients whose disease had progressed on platinum-based therapy to either pembrolizumab or investigator’s choice of chemotherapy (vinflunine, paclitaxel, or docetaxel), pembrolizumab demonstrated significantly